Geoff Duyk, M.D., Ph.D.

Geoff Duyk, M.D., Ph.D.

Scientific Advisor
Managing Director, TPG Growth

Prior to joining Texas Pacific Group Ventures as Managing Director in 2004, Dr. Geoff Duyk served on the Board of Directors and was President of Research & Development at Exelixis where he led a 550+ person group focused on the discovery and development of small molecule therapeutics. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals. As Vice President of Genomics at Millennium, Dr. Duyk was responsible for building and leading the informatics, automation, DNA  sequencing and genotyping groups as well as the mouse and human genetics group. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the human genome project.

Dr. Duyk currently serves on the boards of directors of: Aerie Pharmaceuticals, Inc.; Amyris, Inc.; Beta Renewables; DNAnexus, Inc.; Ebes; Elevance Renewable Sciences, Inc.; Epirus Biopharmaceuticals; Galleon Pharmaceuticals, Inc.; Genomatica; and Karos Pharmaceuticals, Inc.

Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute.